As a transdermal continuous glucose monitoring system and transdermal drug delivery

Echo Therapeutics has provided update on the development of its needle-free Symphony tCGM System, as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system, and its Prelude SkinPrep system for transdermal drug delivery.

The company’s management has reiterated its expectation that 2010 will be a transformative year as Echo completes the development and regulatory review of its products and anticipates generating initial revenues.

Echo is developing the Symphony tCGM System for patients with diabetes and for use in hospital critical care units. The company is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for transdermal drug delivery of a wide range of topical reformulations of widely-used, FDA-approved products.

Patrick Mooney, chairman and chief executive officer of Echo Therapeutics, said: “Our primary focus is the successful completion of a critical care study with a commercially ready Symphony system, which we believe will be the basis for us to receive FDA approval for Symphony.

“In addition, we anticipate the completion of a clinical trial by Ferndale using the Prelude SkinPrep system for a reduced time and enhanced delivery of lidocaine. This will result in a near-term filing of a 510k application with the FDA. These events will enable us to begin manufacturing scale-up for product validation and planned product launch in 2010.”